$3.17
2.46% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US68621F1021
Symbol
ORGO

Organogenesis Holdings Stock price

$3.17
+0.19 6.20% 1M
-0.36 10.20% 6M
-0.03 0.94% YTD
+0.53 20.08% 1Y
-0.67 17.45% 5Y
-6.58 67.49% 10Y
-6.58 67.49% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.08 2.46%
ISIN
US68621F1021
Symbol
ORGO
Sector

Key metrics

Market capitalization $402.13m
Enterprise Value $293.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.64
P/S ratio (TTM) P/S ratio 0.88
P/B ratio (TTM) P/B ratio 1.09
Revenue growth (TTM) Revenue growth 5.36%
Revenue (TTM) Revenue $458.76m
EBIT (operating result TTM) EBIT $5.19m
Free Cash Flow (TTM) Free Cash Flow $-7.00m
Cash position $109.97m
EPS (TTM) EPS $-0.16
P/E forward 45.29
P/S forward 0.81
EV/Sales forward 0.60
Short interest 26.36%
Show more

Is Organogenesis Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Organogenesis Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Organogenesis Holdings forecast:

Buy
75%
Hold
25%

Financial data from Organogenesis Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
459 459
5% 5%
100%
- Direct Costs 111 111
2% 2%
24%
348 348
6% 6%
76%
- Selling and Administrative Expenses 295 295
10% 10%
64%
- Research and Development Expense 48 48
5% 5%
10%
23 23
20% 20%
5%
- Depreciation and Amortization 17 17
12% 12%
4%
EBIT (Operating Income) EBIT 5.19 5.19
59% 59%
1%
Net Profit -20 -20
450% 450%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Organogenesis Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organogenesis Holdings Stock News

Positive
Seeking Alpha
3 days ago
ORGO's main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. They have a Phase 3 trial on ReNu knee-osteoarthritis with data anticipated by September 2025. Its potential BLA filing could eventually unlock the injectable OA market. CMS skin-substitute LCD was postponed to January 2026. This regulatory standard will require more robust evidence...
Neutral
Seeking Alpha
about one month ago
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief Financial Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Operator Welcome, ladies and gentlemen, to the First ...
Neutral
GlobeNewsWire
about one month ago
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025.
More Organogenesis Holdings News

Company Profile

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Head office United States
CEO Gary Gillheeney
Employees 869
Founded 1985
Website investors.organogenesis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today